Maria Solaki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Maria Solaki has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
Agnes B. Renner
Augenarztpraxis Regensburg Regensburg Germany
1 shared publication- Andreas Robert Janecke
Department of Pediatrics I, Medical University of Innsbruck, 6020 Innsbruck, Austria
1 shared publication - André Messias
University of São Paulo
1 shared publication - Astrid S. Plomp
Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands; Amsterdam Reproduction & Development, Amsterdam, The Netherlands
1 shared publication - Balázs Varsányi
Department of Ophthalmology, Semmelweis University, Mária Str. 39, 1085 Budapest, Hungary
1 shared publication Beatrice Bocquet
National Reference Centre for Inherited Sensory Diseases, Institute for Neurosciences of Montpellier (INM) University of Montpellier, INSERM Montpellier France
1 shared publication
Latest Publications
- Open Access
- 14 April 2022
- Published by Wiley in Human Mutation
- Vol. 43 (7) , 832-858
Comprehensive variant spectrum of the CNGA3 gene in patients affected by achromatopsia
Achromatopsia (ACHM) is a congenital cone photoreceptor disorder characterized by impaired color discrimination, low visual acuity, photosensitivity, and nystagmus. To date, six genes have been associated with ACHM (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6), the majority of these being implicated in the cone phototransduction cascade. CNGA3 encodes the CNGA3 subunit of the cyclic nucleotide-gated ion channel in cone photoreceptors and is one of the major disease-associated genes for ACHM. Herein, we provide a comprehensive overview of the CNGA3 variant spectrum in a cohort of 1060 genetically confirmed ACHM patients, 385 (36.3%) of these carrying "likely disease-causing" variants in CNGA3. Compiling our own genetic data with those reported in the literature and in public databases, we further extend the CNGA3 variant spectrum to a total of 316 variants, 244 of which we interpreted as "likely disease-causing" according to ACMG/AMP criteria. We report 48 novel "likely disease-causing" variants, 24 of which are missense substitutions underlining the predominant role of this mutation class in the CNGA3 variant spectrum. In addition, we provide extensive in silico analyses and summarize reported functional data of previously analyzed missense, nonsense and splicing variants to further advance the pathogenicity assessment of the identified variants.
- 14 April 2022
- Published by Wiley in Human Mutation
- Vol. 43 (7) , 832-858
Open AccessComprehensive variant spectrum of the CNGA3 gene in patients affected by achromatopsia
Achromatopsia (ACHM) is a congenital cone photoreceptor disorder characterized by impaired color discrimination, low visual acuity, photosensitivity, and nystagmus. To date, six genes have been associated with ACHM (CNGA3, CNGB3, GNAT2, PDE6C, PDE6H, and ATF6), the majority of these being implicated in the cone phototransduction cascade. CNGA3 encodes the CNGA3 subunit of the cyclic nucleotide-gated ion channel in cone photoreceptors and is one of the major disease-associated genes for ACHM. Herein, we provide a comprehensive overview of the CNGA3 variant spectrum in a cohort of 1060 genetically confirmed ACHM patients, 385 (36.3%) of these carrying "likely disease-causing" variants in CNGA3. Compiling our own genetic data with those reported in the literature and in public databases, we further extend the CNGA3 variant spectrum to a total of 316 variants, 244 of which we interpreted as "likely disease-causing" according to ACMG/AMP criteria. We report 48 novel "likely disease-causing" variants, 24 of which are missense substitutions underlining the predominant role of this mutation class in the CNGA3 variant spectrum. In addition, we provide extensive in silico analyses and summarize reported functional data of previously analyzed missense, nonsense and splicing variants to further advance the pathogenicity assessment of the identified variants.